Cargando…
Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model
Untreated malaria can progress rapidly to severe forms (<24 h). Moreover, resistance to antimalarial drugs is a threat to global efforts to protect people from malaria. Given this, it is clear that new chemotherapy must be developed. We contribute new data about using methylene blue (MB) to cure...
Autores principales: | Dormoi, Jérôme, Amalvict, Rémy, Gendrot, Mathieu, Pradines, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611243/ https://www.ncbi.nlm.nih.gov/pubmed/36297466 http://dx.doi.org/10.3390/pharmaceutics14102031 |
Ejemplares similares
-
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model
por: Dormoi, Jérome, et al.
Publicado: (2013) -
Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum
por: Gendrot, Mathieu, et al.
Publicado: (2021) -
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model
por: Souraud, Jean-Baptiste, et al.
Publicado: (2012) -
In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
por: Dormoi, Jérome, et al.
Publicado: (2014) -
Comparative Assessment of the Sensitivity of Ten Commercial Rapid Diagnostic Test Kits for the Detection of Plasmodium
por: Gendrot, Mathieu, et al.
Publicado: (2022)